Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Biogen Japan Sets to Quadruple Sales in 2 Years: New Chief
May 19, 2015
-
REGULATORY Panel OKs Sovaldi for Medical Subsidy, Monthly Copay at 10,000-20,000 Yen
May 19, 2015
-
BUSINESS Daiichi Sankyo Exits Global Hybrid Biz Model, Now Focuses on Innovation
May 18, 2015
-
REGULATORY PAFSC Second Committee to Discuss Gilead’s Combination Hepatitis C Treatment on May 28
May 15, 2015
-
REGULATORY Chuikyo Reps Discuss HTA, Re-Pricing as Sovaldi Lands in Japan
May 14, 2015
-
REGULATORY Sovaldi’s 5 Million Yen Price Tag OK’d for 12-Week Regimen, Listing on May 20
May 13, 2015
-
BUSINESS Ono to Expand Cancer-Specialized Rep Force to 150 by October Aiming for Additional Indications for Opdivo
May 13, 2015
-
BUSINESS Astellas Earnings Buoyant on Xtandi, Overseas Sales Offset Japan Fall
May 12, 2015
-
REGULATORY Chuikyo to Discuss Listing of Gilead’s Sovaldi on May 13; Listing Could Take Place This Month
May 11, 2015
-
REGULATORY 10-Year Reexamination Period Possible for Repositioned Drugs under Sakigake System: Official
May 8, 2015
-
ACADEMIA MHLW-Funded Study Calls for Use-Based Development Plans for Combination Drugs
May 7, 2015
-
BUSINESS Nichi-Iko Most Favored Maker of Plavix Generics: Survey
May 1, 2015
-
BUSINESS Daiichi Sankyo Cuts FY2014 Forecasts on Write-Off Loss Tied to Zelboraf
April 30, 2015
-
REGULATORY MOF Presses for 80% Generic Share Target by FY2017
April 28, 2015
-
REGULATORY Number of Topics Discussed by PAFSC Second Committee Exceeds that of First Committee for 1st Time in 10 Years: Jiho Tally
April 28, 2015
-
REGULATORY AMED, JPMA Discussing Joint Use of Compounds, with Policy Announcement Expected in Early June: Dr Suematsu of AMED
April 27, 2015
-
BUSINESS Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
-
REGULATORY LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
-
REGULATORY MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap
April 23, 2015
-
BUSINESS Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…